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Cerebrotendinous Xanthomatosis: diversity
of presentation and refining treatment with
chenodeoxycholic acid
Mahjabin Islam1, Nigel Hoggard2 and Marios Hadjivassiliou1*
Abstract
Background: Cerebrotendinous xanthomatosis (CTX) is a rare but treatable neurometabolic disorder of lipid storage
and bile acid synthesis. Whilst CTX is said to present with the classic triad of juvenile onset cataracts, tendon
xanthomata and progressive ataxia, the diversity of presentation can be such that the diagnosis may be substantially
delayed resulting in permanent neurological disability.
Methods: A retrospective review of the clinical characteristics and imaging findings of 4 patients with CTX presenting
to the Sheffield Ataxia Centre over a period of 25 years.
Results: Although CTX-related symptoms were present from childhood, the median age at diagnosis was 39 years.
Only 1 of the 4 cases had tendon xanthomata, only 2 cases had juvenile onset cataracts and 3 had progressive ataxia
with one patient presenting with spastic paraparesis. Serum cholestanol was elevated in all 4 patients, proving to be a
reliable diagnostic tool. In addition, cholestanol was raised in the CSF of 2 patients who underwent lumbar puncture.
Despite treatment with chenodeoxycholic acid (CDCA) and normalization of serum cholestanol, CSF cholestanol
remained high in one patient, necessitating increase in the dose of CDCA. Further adjustments to the dose of CDCA in
the patient with raised CSF cholestanol resulted in slowing of progression. Two of the patients who have had the
disease for the longest continued to progress, one subsequently dying from pneumonia.
Conclusion: A high index of suspicion for CTX, even in the absence of the classical triad is essential in reaching such
diagnosis. The earlier the diagnosis and treatment, the better the outcome.
Keywords: Cerebrotendinous xanthomatosis, Cholestanol, Chenodeoxycholic acid, Tendon Xanthomata, Early onset
cataracts, CYP27A1, CTX, Ataxia
Introduction
Cerebrotendinous xanthomatosis (CTX) is a treatable
neurometabolic disorder of lipid storage and bile acid
synthesis. Mutations of the CYP27A1 gene result in defi-
ciency of sterol 27-hydroxylase, an essential enzyme for
conversion of cholesterol to chenodeoxycholic (CDCA)
and cholic acids [1]. This results in reduced levels of
Chenodeoxycholic acid; the process interrupts the feed-
back regulation of cholesterol 7-alpha-hydroxylase,
which is the rate-limiting step in bile acid synthesis. The
overall effect of this interruption is formation of choles-
tanol which is a metabolite of cholesterol that cannot be
excreted. It therefore accumulates in plasma and is de-
posited in various lipophilic tissues such as brain with a
preference for the cerebellum, eyes, resulting in cataracts
and tendons resulting in tendon xanthomata [2].
Worldwide, more than 300 patients have been reported
with a variety of mutations. An estimated prevalence of
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CTX in Caucasian population is 1:50,000 (patients with
R362C CYP27A1 mutation), however, there is a strong
possibility of under diagnosis due to its diverse manifesta-
tions [3]. Clinical presentation remains variable, even in
patients within the same family or between identical twins
[4]. CTX can present with any of the following symptoms:
Infantile onset diarrhoea, childhood and juvenile onset
cataracts, adolescent to young adult-onset tendon xantho-
mata, and childhood or adult-onset progressive neurologic
dysfunction with one or more of the following: cerebellar
ataxia, pyramidal and extrapyramidal signs, learning diffi-
culties and intellectual disability, behavioural and psychi-
atric disturbances, dementia, peripheral neuropathy, and
seizures [5]. The classic triad of this syndrome consists of
early onset cataracts, tendon xanthomata, predominantly
involving Achilles tendons, and cerebellar ataxia. We
present here four cases of CTX with variable clinical pre-
sentations. We also discuss how to optimize treatment
with chenodeoxycholic acid based on CSF measurements
of cholestanol, something that has never been reported
previously.
Methods
This report is based on a retrospective observational
case series of all patients with CTX regularly attending
the Sheffield Ataxia Centre, Sheffield Teaching hospitals
NHS Trust, Royal Hallamshire Hospital, Sheffield, UK.
The South Yorkshire Research Ethics Committee has
confirmed that no ethical approval is indicated given
that all investigations/interventions were clinically indi-
cated and did not form part of a research study. The
Sheffield Ataxia Centre cares for over 2500 patients with
progressive ataxia and these are the only 4 patients with
CTX highlighting the rarity of the condition. In three
patients the diagnosis of CTX was made at the Sheffield
Ataxia Centre, based on clinical suspicion and subse-
quent cholestanol and genetic testing, whilst the 4th pa-
tient was diagnosed with CTX elsewhere and referred to
the Sheffield Ataxia Centre for consideration of treat-
ment. All patients received treatment with CDCA. Pa-
tients were followed up on a 6–12 monthly basis and
serum cholestanol and MR Spectroscopy was used as a
monitoring tool.
Cases
Patient 1
A 42-year-old man was referred to the Sheffield Ataxia
Centre with a history of early onset cataracts, gait in-
stability and cognitive difficulties. At the age of 8, his
parents became concerned about his poor vision which
may have contributed to his underperformance at
school. He first came to medical attention because of
tonic clonic seizures. An EEG revealed frequent general
bursts of rhythmic 2–3 Hz activity but no lateralization.
His performance at school deteriorated further. He suf-
fered from severe anxiety and became very disruptive in
the classroom resulting in social isolation. He was re-
ferred to a special school. At the age of 16, he was
reviewed by a paediatric neurologist who found him to
have pes cavus and bilateral increased tone in lower
limbs, intention tremor in both arms and truncal ataxia.
No diagnosis was made at that time. His visual disturb-
ance was managed with visual aids until the age of 24
when he had bilateral extra capsular cataract extraction.
His epilepsy was well controlled with phenytoin and he
managed his day to day activities with support from his
carer until the age of 35. There was no family history of
any neurological problems.
Examination revealed nasal speech, severe dysarthria,
marked ataxia of limbs and gait and tendon xanthomata
in both the Achilles tendons. His carer highlighted the
deteriorating cognition resulting in poor memory, con-
centration and diminished intellectual abilities, all grad-
ually worsening over many years. The suspicion of CTX
was based on the typical clinical findings. Serum choles-
tanol was elevated at 53 μmol/L (normal range 3–
16 μmol/L). At the time genetic testing for CTX was not
readily available. For confirmation, examination of plasma
and urinary bile acids were done to identify abnormal bile
acid intermediates, notably glucuronides of pentols and
hexols. His urinary bile acid analysis showed grossly ab-
normal peak of Cholestane-Pentol-Glucuronide, a charac-
teristic abnormality seen in CTX. Other abnormalities
included increased glucuronides of cholestane-tetrol,
hexol and heptol as well as taurine and glycine conjugates
of 23-hydroxycholate. MR imaging showed abnormal
white matter primarily affecting the cerebellum (Fig. 1 a).
Despite the significant neurological disability, he was
started on CDCA at a dose of 750 mg/day. His cholesta-
nol level gradually reduced (53 μmol/L, 12 μmol/L,
7 μmol/L) over a period of 1 year. Clinically, there was a
slight objective improvement in his speech, based on
clinical examination and comments by his carers. He
had a PEG tube inserted at the age of 44 due to recur-
rent aspirations and his communication had to be
assisted with light writer. Although his biochemical pa-
rameters improved with CDCA, he continued to pro-
gress and died of pneumonia at the age of 45. Table 1
summarizes the clinical characteristics of all 4 patients.
Patient 2
A 37-year-old lady presented primarily because of deteri-
orating balance and a background of mild cognitive
problems. She was labelled as having Asperger’s syn-
drome. Notable in her past medical history was early on-
set cataracts at the age of 8 years which were extracted
when she was 9. She suffered from diarrhoea when she
was a child.
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Her mother reported that she had been clumsy from a
young age. She reached normal developmental mile-
stones, particularly in regards to motor development.
Apart from early onset hypertension and osteoporosis
she was reasonably well and mobile until the age of 34
when she became unsteady on her feet and extremely fa-
tigued. She started having frequent falls and fractured
her left ankle following a fall. She had 3 siblings none of
whom had any neurological symptom. Both parents were
asymptomatic.
Neurological examination revealed limb and gait
ataxia, very brisk reflexes and extensor plantars but no
tendon xanthomata. She was unable to do tandem walk.
MR imaging showed extensive white matter changes
in cerebellum, high signal in inferior olives bilaterally,
there was also increased signal changes supratentorially,
involving corpus callosum, internal capsule and corona
radiata, and white matter tract specifically of the corti-
cospinal tract and optic radiation (Fig. 1b).
Because of the history of early onset cataracts, diar-
rhoea and ataxia, serum cholestanol was measured and
found to be high at 145 μmol/L. A diagnosis of CTX was
made and she was started on CDCA 750mg per day.
She initially improved; physiotherapy assessments
showed improvement in 10m walk test and single leg
stand test. Serum cholestanol normalised with the treat-
ment but this took 2 years.
Despite having normal serum cholestanol, her mobility
then started to deteriorate. She became increasingly
more dysarthric and developed swallowing difficulties.
Analysis for 7 alpha hydroxy 4-cholesten-3-one in
plasma (another way of measuring the effectiveness of
CDCA) showed it to be within normal limits (46 nmol/L,
normal level < 100 nmol/L). The advice based on this test
was that she should continue with the current dose of
CDCA.
Six years after the start of treatment with CDCA at a
dose of 750mg/day, CSF cholestanol was measured and
was found to be five times higher when compared to
CSF of healthy controls. As a result, the dose to CDCA
was increased to 1000mg per day. Repeat CSF after a
year on the higher dose, showed the CSF cholestanol to
have reduced significantly but still higher than normal
controls. Unfortunately the patient could not tolerate a
higher dose of CDCA, and compliance became an issue
due to nausea and vomiting. The family were reluctant
for her to have any further medical interventions (e.g. re-
peat CSF studies and imaging) and currently she is cared
for at home by her parents. Her condition has deterio-
rated further but the rate of deterioration was felt to be
slower (according to her family who cared for her on a
daily basis) after increasing the dose of CDCA (Table 2).
Patient 3
A 37-year-old gentleman was referred to the Sheffield
Ataxia Centre with worsening speech and increased ten-
dency to fall. His symptoms started at the age of 15. He
denied any visual problem. He developed urgency and
frequency of micturition. By the time he was seen, he
was largely confined to a wheelchair and requiring help
from at least one person to be able to walk. He had a
background of learning difficulties, attending a special
school from a young age. He denied any diarrhoea or
other bowel symptom. He came from a family of three
brothers and two sisters none of whom had similar
symptoms. Both parents, in consanguineous marriage,
were in their eighties and well.
Fig. 1 Axial T2 weighted imaging of patient 1, showing bilateral hyper intense lesions involving the dentate nuclei and the deep cerebellar white
matter (a). Supratentorial imaging (Patient 2) shows white matter tract involvement, specifically of the corticospinal tract and optic radiation (b)
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Neurological examination showed no evidence of cata-
ract or tendon xanthomata. His speech was very dysarth-
ric, and he had limb and gait ataxia, increased tone,
pathologically brisk reflexes in both legs with bilateral
extensor plantar responses. He also had tremor affecting
both arms.
MRI of the brain showed signal change within the
cerebellar hemispheres, which was associated with sig-
nificant volume loss. There was a combination of low
signal change suspected to be due to calcification (con-
firmed on CT – Fig. 2a) and raised signal change in the
rest of the cerebellar hemispheres extending into the
cerebellar peduncles bilaterally (Fig. 2b).
A diagnosis of CTX was not immediately suspected
based on the clinical and imaging findings but the early
onset of ataxia with parental consanguinity was strongly
suggestive of an autosomal recessive genetic cause. Gen-
etic testing using next-generation sequencing (NGS)
showed him to be homozygous for the CYP27A1c.157del,
p.(Arg53fs) mutation, confirming the diagnosis of CTX.
At the time of diagnosis, serum cholestanol was high
(125 μmol/L) as expected. Baseline CSF cholestanol
sample (before treatment) revealed high titre of
2.5 μmol/L when compared to healthy control CSF sam-
ples (0.252–0.376 μmol/L). He was started on CDCA at
a dose of 750 mg/day. After 6 months of treatment, he
and the family reported improvement in the severity of
the tremor and this was confirmed on neurological
examination; however, gait instability remained un-
changed although his serum Cholestanol level dropped
to 41 μmol/L. No further updates are yet available.
Patient 4
This 27-year-old man presented with a 3-year history of
stiffness and then weakness and sensory disturbance af-
fecting both legs. He had a history of infantile onset
diarrhoea which persisted throughout his life. He was
extensively investigated for coeliac disease, but biopsy
proved to be negative. He had normal developmental
milestones and had been quite active in sports during
childhood and in his early 20’s. In fact he was playing
Taekwondo until the onset of his symptoms.
Examination revealed nystagmus on lateral gaze, brisk
jaw jerk, increased tone bilaterally in arms and legs with
Table 1 Summary of clinical characteristics in 4 patients with CTX
Patients Sex Age at symptom onset Age at diagnosis Infantile onset
Diarrhoea
Intellectual
Disability
Tendon
Xanthomata
Early onset
cataract
Patient 1 M 8 42 No Yes Yes Yes
Patient 2 F 8 37 Yes Yes No Yes
Patient 3 M 15 37 No Yes No No
Patient 4 M 25 41 Yes No No No
Patients Pyramidal signs Extrapyramidal signs Epilepsy Dementia Neuropathy Osteoporosis
Patient 1 Yes No Yes Yes Yes No
Patient 2 Yes No No No No Yes
Patient 3 Yes Yes No No Yes No
Patient 4 Yes No No No Yes No
Fig. 2 CT (a) and MRI (b) images from Patient 3 showing evidence of cerebellar calcification which although rare can be a feature of CTX
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pathologically brisk reflexes, and extensor plantar re-
sponses. He walked with a rather spastic gait and had bi-
lateral pes cavus. His parents were in good health, with
the only medical problems being coeliac disease of the
mother. He was thought to have hereditary spastic para-
paresis (HSP). Initial limited genetic testing for HSP was
negative. He was followed up in neurology and managed
with antispasmodics. His condition gradually deterio-
rated and he eventually ended up wheelchair bound due
to the severity of the spasticity.
The stored DNA sample was again tested using ex-
tended HSP panel. He was found to be homozygous for
a pathogenic mutation of the CYP27A1 gene. His cho-
lestanol level was 112 μmol/L at baseline.
MRI of brain showed cerebellar atrophy, significantly
worse in the hemispheres than the vermis with signal
change around the dentate nucleus extending into the
cerebellar peduncles. His spinal MRI also showed signal
changes mainly involving lateral corticospinal tracts
(Fig. 3a, b).
He has been started on chenodeoxycholic acid recently
and is under review.
Discussion
CTX is an autosomal recessive lipid storage disorder
caused by mutations in the CYP27A1 gene which leads
to abnormal deposition of cholestanol in different lipo-
philic tissues resulting in various neurological and non-
neurological manifestations. It was first described in
1937 by Van Bogaert and colleagues [6]. Chenodeoxy-
cholic acid replacement, the treatment of choice, was re-
ported first in 1975 by Salen et al. and subsequently by
Berginer [7, 8].
We describe here a series of 4 patients with CTX who
presented with diverse manifestations but eventually
were diagnosed with this rare condition. In addition to
the clinical characteristics, we provide detailed imaging
data and our experience in the treatment with CDCA
aided by CSF monitoring of cholestanol. This variability
in presentation has been considered to be the cause of
delay in diagnosis. Whilst in the presence of the classic
triad of early onset cataracts, tendon xanthomata and
progressive ataxia often with pyramidal signs all neurolo-
gists should be alerted to the possibility of CTX, our co-
hort shows that this triad was only seen in 25% of cases.
This diagnostic triad fails to highlight another important
feature of this disease which is the cognitive deficits that
seem to be prevalent at a young age interfering with
schooling and being misdiagnosed as behavioral or psy-
chological problems or, as in one case here Asperger’s
syndrome. It would be advisable to test (using serum
cholestanol) all patients with early onset cataracts even
in the absence of any neurological deficits to facilitate
earlier diagnosis. The same is true for patients with clear
evidence of tendon xanthomata. Such an approach may
facilitate early diagnosis and treatment and may prevent
Table 2 Summary of biochemical and genetic investigations
serum cholestanol
at diagnosis normal
< 5 μmol/L
CSF cholestanol
reference range (0.252–0.376 μmol/L)
based on healthy controls)
serum Cholestanol
after treatment
Urine Bile
acid alcohol
Genetic Confirmation
Patient 1 53 not done 7 High Not done
Patient 2 145 1.06 μmol/L on standard dose,
0.49 μmol/L after CDCA dose increase
10 High CYP27A1: c.1184 + 1G > A(;)
1263 + 1G > A, p.(?)(;)(?)
Patient 3 125 2.5 (μmol/L) before treatment 41 Not done CYP27A1c.157del,p.(Arg53fs)
Patient 4 112 not done not repeated as yet Not done CYP27A1: c.[1183 > T];[1183C >
T], p[(Arg395Cys)];p[(Arg395Cys)]
Fig. 3 Axial T2 MRI spinal images (Patient 4) showing signal changes affecting mainly lateral Corticospinal tracts (magnified in image b)
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permanent neurological disability as was the case in all 4
of our patients [5]. The mean age at diagnosis of CTX in
this cohort was 39 years whilst the mean age at symptom
onset was 14. This means that the mean delay in the
diagnosis was 25 years.
As described by many, the importance of diagnosing this
neurodegenerative condition is because it is potentially
treatable. The treatment can reverse, stabilize, or prevent
accumulation of cholestanol in CNS slowing the develop-
ment or stopping the progression of neurological symptoms
[5, 9]. A cross-sectional observational study demonstrated
worse outcome and significant limitation in ambulation
and cognition in patients with CTX diagnosed after the age
of 25 despite treatment with chenodeoxycholic acid [10].
To aid early diagnosis, Mignarri et al. devised a suspi-
cion index composed of weighted scores assigned to dif-
ferent indicators which follows a diagnostic flow chart to
aid early detection [11]. In this scoring system, very
strong indicators include family history (sibling with
CTX) and tendon xanthomata. Other parameters include
consanguineous parents, juvenile cataracts, childhood-
onset chronic diarrhoea, prolonged unexplained neo-
natal jaundice or cholestasis, ataxia and/or spastic para-
paresis, dentate nuclei signal alterations on MRI,
intellectual disability and/or psychiatric disturbances.
Moderate criteria include early osteoporosis, epilepsy,
parkinsonism and polyneuropathy. All 4 cases described
here, scored 100 or more using the suspicion index tool
developed by Mignarri et al. and qualified for serum
cholestanol measurement. This supports the use of this
tool for early diagnosis.
CDCA has been shown to be very effective in reducing
the serum cholestanol in CTX patients and this has been
our experience with this cohort [12]. Yet 2 of our pa-
tients continued to progress after some initial minor im-
provement. One patient died due to pneumonia at the
age of 45. He was extremely disabled, confined to a
wheelchair and required PEG feeding. In patient 2, pro-
gressive clinical deterioration and lack of improvement
despite normalisation of serum cholestanol let us to
examine the CSF. We were able to demonstrate that the
CSF cholestanol remained high despite normal serum
cholestanol and that increasing the dose of CDCA re-
duced CSF cholestanol further.
Previous work suggests that the level of CSF cholesta-
nol can be as high as 20 times the normal healthy popu-
lation and that treatment with CDCA reduces CSF
cholestanol by three fold [13]. The question here, is why
does normalisation of serum cholestanol not accompan-
ied by normalisation of CSF cholestanol? Could this be
the reason why some patients do not respond that well
to CDCA? We were able to show that adjustments to
the dose of CDCA can result in further decrease of the
CSF cholestanol. The clinical benefit was minimal prob-
ably because the disability was so severe.
The precise pathophysiology of neurological damage
in CTX remains unclear. Some postulate that raised level
of apolipoprotein B concentration in CSF permits in-
creased transportation of cholesterol and cholestanol
across the blood-brain barrier. Accumulation of choles-
tanol at a high concentration in the brain tissue initiates
apoptotic pathways which eventually lead to neuronal
death. Chenodeoxycholic acid treatment re-establishes
selective permeability of the defective blood brain barrier
and normalizes the level of sterols and apolipoprotein in
CSF, therefore minimizes further damage [13]. However,
the existing deposits of cholestanol may still perpetuate
the apoptosis. Of interest, is the observation that choles-
tanol deposition seems to have a predilection for the
cerebellum, at least in those classic cases. It remains ob-
scure why this should be the case or why in some cases
(less common) the deposition affects primarily the spinal
cord. This predilection of cholestanol deposition in the
cerebellum was suggested to be the result of low abun-
dance of CYP46A1, the principal cholesterol 24-
hydroxylase, in the cerebellum [14].
A retrospective study of 56 patients with CTX by Bi-
anca et al. concluded that patients who are diagnosed
and treated before the age of 24 had complete resolution
of their neurological symptoms and prevented the devel-
opment of new neurological symptoms at followed up
[5]. This emphasises the importance of early diagnosis
and treatment in preventing long term disability.
The increased availability of genetic testing and the in-
clusion of CTX in both ataxia and HSP panels is likely
to aid the diagnosis of CTX. As noted in one of our
cases, spastic paraparesis can be the first presentation of
CTX, therefore should be considered as a part of the dif-
ferential diagnosis of chronic myelopathy particularly if
there is signal change in the cord on spinal imaging [15].
However, there is a need for a high index of suspicion in
younger population with a much more subtle phenotype
that may just include learning and cognitive difficulties
often with behavioural problems for which cholestanol
estimation should be part of the diagnostic workup.
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